

PATENT

ATTORNEY DOCKET NO. 06368/005001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : D'Apice et al. Art Unit: 4804
Serial No.: 08/378,617 Examiner: Crouch, D.
Filed : 01/26/95
Title : MATERIALS AND METHODS FOR MANAGEMENT OF HYPERACUTE
REJECTION IN HUMAN XENOTRANSPLANTATION

Box AF
Assistant Commissioner for Patents
Washington, DC 20231

DECLARATION UNDER 37 C.F.R. § 1.132

I, Robert John Crawford, hereby declare as follows:

1. That I am employed as Research Administrator at BresaGen, 38-39 Winwood St., Thebarton, South Australia, and have been so employed since 1993;

2. That I received a Ph.C in Pharmacy from the University of Adelaide in 1965, a Bachelor of Science Degree in Biochemistry from the University of Adelaide in 1971 and a Ph.D in Biochemistry from the University of Adelaide in 1977;

3. That I am one of the named inventors for the above-referenced patent application;

4. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, code of Federal Regulations, Section 1.56(a);

5. With reference to the minor errors in the porcine α -1,3 galactosyltransferase nucleic acid (SEQ ID NO: 7) and amino acid (SEQ ID NO: 10) sequences brought to the attention of the Examiner in an Information Disclosure Statement submitted October 16, 1995 in the above-referenced patent application, I make the following remarks;


6. That I, or individuals under my supervision, have repeated the sequencing of the relevant same porcine α -1,3 galactosyltransferase cDNA clone described in Example 6 of the specification of the above-referenced patent application;

7. Due to difficulties in reading the original sequencing gel shown in the attached sheet of gel images, nucleotide 463 was designated an A (panel A). Upon repeating the sequencing of the same cDNA clone, the sequence was clear in this region, and indicated that nucleotide 463 should be a T (panel B). Based on this nucleotide change, the amino acid of corresponding codon 125 should be tyrosine rather than asparagine;

8. A clerical mistake led to the errors at nucleotides 1071 and 1072. Both the original sequencing gel (panel C) and the repeat sequencing gel (panel D) indicate that nucleotides 1071 and 1072 should be CC, rather than AA. The amino acids of

corresponding codons 327 and 328 should be phenylalanine-leucine rather than leucine-isoleucine;

6. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

By: 
John Robert Crawford

Dated: 21 July 1997

8964.M11